Loading
The FIGO review of trophoblastic disease from molar pregnancy to choriocarcinoma and the rare placental-site and epithelioid tumours: hCG surveillance, the risk score, single-agent or EMA/CO chemotherapy, surgery, and immunotherapy for resistant disease.
FIGO Cancer Report chapter covering hydatidiform mole and its follow-up, the FIGO 2000 staging and scoring of gestational trophoblastic neoplasia, single-agent therapy for low-risk and EMA/CO for high-risk disease, induction etoposide-cisplatin for ultra-high-risk disease, salvage regimens, the role of hysterectomy and metastasectomy, management of placental-site and epithelioid trophoblastic tumours, immunotherapy for resistant disease, and follow-up and future pregnancy.
The standard-of-care rows on all three trophoblastic pages follow this report and the national centres it describes.
Shares Dactinomycin (actinomycin D), High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk), Methotrexate, Etoposide.
Shares Placental-site trophoblastic tumour and epithelioid trophoblastic tumour, Etoposide, Cisplatin.
Shares Placental-site trophoblastic tumour and epithelioid trophoblastic tumour, Etoposide, Cisplatin.
Shares Dactinomycin (actinomycin D), Methotrexate.
Shares Placental-site trophoblastic tumour and epithelioid trophoblastic tumour, Dactinomycin (actinomycin D), High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk), Methotrexate.
Shares Placental-site trophoblastic tumour and epithelioid trophoblastic tumour, Dactinomycin (actinomycin D), High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk), Methotrexate.
Shares Etoposide, Cisplatin, Pembrolizumab.
Shares Etoposide, Cisplatin, Pembrolizumab.